Javascript must be enabled to continue!
Alteration of Gut Microbiome in Lung Cancer Patients
View through CrossRef
ABSTRACT
Lung cancer is the leading cause of cancer death. Better understanding of factors and pathways involved in lung cancer is needed to improve diagnose and treatment strategies. Recent studies have provided insights into the possible correlation between intestinal dysbiosis and cancer development. Although the immunological relationship between gut and lung had been suggested by many researches, however, to date, no study had investigated the characterization of gut microbiome in treatment naïve lung cancer patients, whether it is distinct from that of health individuals and contribute to the onset and development of lung cancer remain unclear. In this study, we investigated whether gut microbiome of lung cancer patients (LC, n=28) is altered compare with that of matched healthy individuals (HC, n=19) by high throughout sequencing of the V3-V4 regions of 16S rDNA in their fecal samples. We also identified microbiota signatures specific for different histological types of lung cancer, including SSC, ADC, and SCLC. The gut microbiome of lung cancer patients is characterized by decreased relative abundance of
Prevotella
, and increased bacteria groups such as
Actinomyces
, and
Streptococcus
, etc. We also detected a mild structural shift in gut microbiome between ADC and SCLC patients. Our results showed that the gut microbiome of lung cancer patients altered significantly compared with healthy individuals. However, the association between microbial dysbiosis and lung cancer is not clearly understood, future studies involving larger cohorts and metagenomics, or metabolomics, may elucidate the correlations between gut microbiota and lung cancer development.
IMPORTANCE
This is the first report to show the alteration of gut microbiome in lung cancer patients. Our results showed that the gut microbiome of lung cancer patients altered significantly compared with healthy individuals.
Title: Alteration of Gut Microbiome in Lung Cancer Patients
Description:
ABSTRACT
Lung cancer is the leading cause of cancer death.
Better understanding of factors and pathways involved in lung cancer is needed to improve diagnose and treatment strategies.
Recent studies have provided insights into the possible correlation between intestinal dysbiosis and cancer development.
Although the immunological relationship between gut and lung had been suggested by many researches, however, to date, no study had investigated the characterization of gut microbiome in treatment naïve lung cancer patients, whether it is distinct from that of health individuals and contribute to the onset and development of lung cancer remain unclear.
In this study, we investigated whether gut microbiome of lung cancer patients (LC, n=28) is altered compare with that of matched healthy individuals (HC, n=19) by high throughout sequencing of the V3-V4 regions of 16S rDNA in their fecal samples.
We also identified microbiota signatures specific for different histological types of lung cancer, including SSC, ADC, and SCLC.
The gut microbiome of lung cancer patients is characterized by decreased relative abundance of
Prevotella
, and increased bacteria groups such as
Actinomyces
, and
Streptococcus
, etc.
We also detected a mild structural shift in gut microbiome between ADC and SCLC patients.
Our results showed that the gut microbiome of lung cancer patients altered significantly compared with healthy individuals.
However, the association between microbial dysbiosis and lung cancer is not clearly understood, future studies involving larger cohorts and metagenomics, or metabolomics, may elucidate the correlations between gut microbiota and lung cancer development.
IMPORTANCE
This is the first report to show the alteration of gut microbiome in lung cancer patients.
Our results showed that the gut microbiome of lung cancer patients altered significantly compared with healthy individuals.
Related Results
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Gut Microbiome Alterations in COVID-19
Gut Microbiome Alterations in COVID-19
Abstract
Since the outset of the coronavirus disease 2019 (COVID-19) pandemic, the gut microbiome in COVID-19 has garnered substantial interest, given its significan...
Quantifying the impact of Human Leukocyte Antigen on the human gut microbiome
Quantifying the impact of Human Leukocyte Antigen on the human gut microbiome
AbstractObjectiveThe gut microbiome is affected by a number of factors, including the innate and adaptive immune system. The major histocompatibility complex (MHC), or the human le...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Impact of urbanization on gut microbiome mosaics across geographic and dietary contexts
Impact of urbanization on gut microbiome mosaics across geographic and dietary contexts
ABSTRACT
This study provides a comprehensive assessment of how urban-rural divides influence gut microbial diversity and composit...
A hidden confounder for microbiome studies: medications used years before sample collection
A hidden confounder for microbiome studies: medications used years before sample collection
ABSTRACT
Medication usage is a known contributor to the inter-individual variability of the gut m...
Analysis of the gut microbiome of Japanese inflammatory bowel disease patients
Analysis of the gut microbiome of Japanese inflammatory bowel disease patients
Abstract
Background
Gut microbiome dysbiosis has been reported in patients with inflammatory bowel disease (IBD). However, gut microbiome of healthy Japanese individuals di...
Abstract 720: Comparison of the gut microbiome between children with solid tumor receiving chemotherapy and healthy children
Abstract 720: Comparison of the gut microbiome between children with solid tumor receiving chemotherapy and healthy children
Abstract
Background: Chemotherapy is commonly used for children with cancer. Intensive chemotherapy can disturb the gut microbiome, which may be associated with trea...

